FDA approves new fibrillation drug

July 2, 2009 at 11:10 AM

WASHINGTON, July 2 (UPI) -- The U.S. Food and Drug Administration announced approval Thursday of Multaq tablets to help maintain normal heart rhythms in patients with heart disorders.

The FDA said Multaq (dronedarone) is designed to treat atrial fibrillation or atrial flutter in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.

Since Multaq might cause critical adverse reactions, including death, in patients with recent severe heart failure, officials said Multag's drug's label will contain a boxed warning, the FDA's strongest warning, cautioning the drug should not be used by such people.

Multaq is manufactured by the French pharmaceutical company Sanofi-Aventis.

Related UPI Stories
Latest Headlines
Trending News
Seattle sea otter learns how to use an inhaler
Catholic conservatives wary of Pope's climate change message
Apple signals delivery of electric car by 2019, report says
Self-impregnated snake in Missouri has another 'virgin birth'
Ancient Roman village found in Germany